The positron emission tomography (PET) scan market is experiencing significant growth, driven by technological advancements, increasing prevalence of chronic diseases, and rising demand for accurate diagnostic tools. PET scans, a type of nuclear medicine imaging, provide detailed images of the body's internal structures and functions, making them invaluable in assessing metabolic processes and diagnosing various conditions.
The global positron emission tomography (PET) scan market size was valued at USD 18.52 billion in 2024. It is projected to grow from USD 19.31 billion in 2025 to USD 27.40 billion by 2032, registering a compound annual growth rate (CAGR) of 5.1% during the forecast period. In 2024, North America led the market, accounting for a 50.59% share.
Top Companies in the Market
- RadNet, Inc. (U.S.)
- Sonic Healthcare Limited (Australia)
- Akumin Inc. (U.S.)
- Apex Radiology (Australia)
- Alliance Medical Limited (U.K.)
- Novant Health (U.S.)
- InHealth Group (U.K.)
- Dignity Health (U.S.)
- Concord Medical (China)
Key Industry Development
In June 2024, AGFA HealthCare signed a new deal with Alliance Medical to implement an advanced cloud-based solution across all of Alliance Medical’s U.K. sites, enhancing diagnostic capabilities and streamlining operations.
Market Drivers & Restraints
Drivers
- Increasing Prevalence of Chronic Diseases: The growing burden of chronic diseases, such as cancer, cardiovascular disorders, and neurodegenerative conditions, drives the demand for advanced diagnostic tools like PET scanners for early detection, accurate staging, and treatment planning.
- Advancements in Imaging Technology: Continuous advancements in PET scanner technology, including hybrid systems (PET/CT and PET/MRI), improved image resolution, and faster scan times, enhance the diagnostic capabilities of PET and improve patient experience.
- Personalized Medicine Approach: PET imaging plays a crucial role in guiding personalized treatment approaches by providing information about disease biology, treatment response, and individual patient characteristics.